IC
MCID: INT143
MIFTS: 61

Interstitial Cystitis (IC)

Categories: Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Interstitial Cystitis

MalaCards integrated aliases for Interstitial Cystitis:

Name: Interstitial Cystitis 12 74 52 58 36 42 15 17 71 32
Painful Bladder Syndrome 52 58 71
Bladder Pain Syndrome 52 58 71
Interstitial Cystitis/painful Bladder Syndrome 52 58
Interstitial Cystitis/bladder Pain Syndrome 52 58
Trigonitis 52 71
Ic/bps 52 58
Ic/pbs 52 58
Chronic Interstitial Cystitis 71
Pelvic Congestion Syndrome 71
Cystitis, Interstitial 43
Pelvic Pain Syndrome 52
Ulcerative Cystitis 12
Pelvic Pain 42
Pbs 52
Ic 52

Characteristics:

Orphanet epidemiological data:

58
interstitial cystitis
Prevalence: 1-5/10000 (Finland),1-5/10000 (United States),1-9/1000000 (Finland); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:13949
KEGG 36 H01551
MeSH 43 D018856
NCIt 49 C27189
SNOMED-CT 67 111409009
ICD10 32 N30.1
MESH via Orphanet 44 D018856
ICD10 via Orphanet 33 N30.1
UMLS via Orphanet 72 C0282488 C0600040 C1720830 more
Orphanet 58 ORPHA37202
UMLS 71 C0152078 C0282488 C0600040 more

Summaries for Interstitial Cystitis

NIH Rare Diseases : 52 Interstitial cystitis (IC) is a chronic condition that causes painful urinary symptoms. Symptoms and severity can vary. Some people may have only mild discomfort, or feel tenderness or pressure in the bladder or pelvis. Others may experience intense bladder pain, urgent or frequent needs to urinate, or pain during sexual intercourse. Symptoms may be constant, or they may come and go. Some people with IC have Hunner's ulcers (areas of inflammation on the bladder wall, identified by cytoscopy ). The exact cause of IC is not known. While the symptoms are similar to those of a bladder infection, IC is not an infection. It occurs more commonly in women, and in people with other chronic pain disorders such as irritable bowel syndrome or fibromyalgia . There is no cure for IC, but there are treatment options to help relieve the symptoms. No single treatment works for all people with IC. Often, people try different treatments or combinations of treatments before finding something that works. Treatment options may include lifestyle changes , oral or topical medications, bladder instillations , neuromodulation therapy , Botox injections in the bladder muscles, and surgery (in rare cases). Without treatment, IC can affect a person's sleep, daily activities, and social life.

MalaCards based summary : Interstitial Cystitis, also known as painful bladder syndrome, is related to cholera and urethral syndrome, and has symptoms including pain and other symptoms associated with female genital organs, mittelschmerz and unspecified symptom associated with female genital organs. An important gene associated with Interstitial Cystitis is NGF (Nerve Growth Factor), and among its related pathways/superpathways are CREB Pathway and PAK Pathway. The drugs Desogestrel and Clindamycin have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and brain, and related phenotypes are abnormality of the menstrual cycle and abnormality of the urethra

MedlinePlus : 42 Interstitial cystitis (IC) is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently. It is far more common in women than in men. The symptoms vary from person to person. Some people may have pain without urgency or frequency. Others have urgency and frequency without pain. Women's symptoms often get worse during their periods. They may also have pain with sexual intercourse. The cause of IC isn't known. There is no one test to tell if you have it. Doctors often run tests to rule out other possible causes of symptoms. There is no cure for IC, but treatments can help most people feel better. They include Distending, or inflating, the bladder Bathing the inside of the bladder with a drug solution Oral medicines Electrical nerve stimulation Physical therapy Lifestyle changes Bladder training In rare cases, surgery NIH: National Institute of Diabetes and Digestive and Kidney Diseases

KEGG : 36 Interstitial cystitis (IC), also referred to as bladder pain syndrome (BPS), is a chronic non-infectious inflammatory condition characterized by recurring discomfort, pain or pressure in the bladder and the surrounding pelvic region. IC/BPS most often affect females compared with males. The affected individuals experience urinary frequency and urgency. The duration of irritative symptoms associated with unpleasant sensation are longer than six weeks duration. At present, there are two major subtypes of IC/BPS: those with or without Hunner lesion, which are also known as ulcerative or non-ulcerative IC/BPS, respectively.

Wikipedia : 74 Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a type of chronic pain that... more...

Related Diseases for Interstitial Cystitis

Diseases in the Interstitial Cystitis family:

Chronic Interstitial Cystitis

Diseases related to Interstitial Cystitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1206)
# Related Disease Score Top Affiliating Genes
1 cholera 32.6 KNG1 IL6 EGF CXCL8
2 urethral syndrome 32.6 UMOD TAC1 P2RX3 NGF IL6 CXCL8
3 low compliance bladder 31.1 P2RX3 NGF
4 acute cystitis 30.9 UPK3A UPK1A UMOD IL6 CXCL8
5 bacteriuria 30.9 UMOD IL6 CXCL8
6 pyelonephritis 30.8 UMOD IL6 CXCL8
7 pyuria 30.8 UPK3A IL6 CXCL8
8 rhinitis 30.7 NGF KNG1 IL6 CXCL8
9 panic disorder 30.6 TACR1 TAC1 IL6 BDNF
10 vesicoureteral reflux 1 30.5 UPK3A UPK1A UMOD CXCL8
11 allergic rhinitis 30.5 TAC1 NGF KNG1 CXCL8
12 irritable bowel syndrome 30.5 TRPV1 TACR1 TAC1 NGF IL6 CXCL8
13 adenomyosis 30.5 NGF IL6 CXCL8 CDH1
14 hydronephrosis 30.5 UPK3A IL6 EGF CXCL8
15 esophagitis 30.5 IL6 EGF CXCL8
16 gastric ulcer 30.4 IL6 EGF CXCL8
17 keratoconjunctivitis 30.4 NGF IL6 CXCL8
18 spinal cord injury 30.4 IL6 CXCL8 BDNF
19 radiculopathy 30.4 TAC1 IL6 CXCL8
20 acute kidney failure 30.4 UMOD KNG1 EGF
21 neuroma 30.3 TRPV1 NGF IL6
22 contact dermatitis 30.3 NGF IL6 CXCL8
23 fibromyalgia 30.3 TACR1 SCN9A P2RX3 NGF IL6 CXCL8
24 allergic hypersensitivity disease 30.3 TACR1 TAC1 KNG1 CXCL8 BDNF
25 adrenal gland pheochromocytoma 30.3 NGF BDNF
26 peptic esophagitis 30.3 TRPV1 IL6 CXCL8
27 urinary tract obstruction 30.3 UPK3A UMOD HBEGF EGF CDH1
28 varicose veins 30.3 KNG1 IL6 CXCL8
29 anxiety 30.3 TAC1 NGF IL6 BDNF
30 duodenal ulcer 30.2 IL6 EGF CXCL8
31 neurogenic bladder 30.1 UPK3A TRPV1 TACR1 TAC1 P2RX3 NGF
32 diarrhea 30.1 TRPV1 TAC1 IL6 CXCL8 CDH1
33 aspiration pneumonia 30.1 TRPV1 TAC1 IL6
34 pyelitis 30.1 UPK1A UMOD IL6 CXCL8
35 pheochromocytoma 30.0 NGF KNG1 IL6 EGF CDH1
36 mononeuropathy 30.0 TRPV1 TAC1 NGF
37 brain edema 30.0 TJP1 KNG1 IL6
38 myofascial pain syndrome 30.0 TRPV1 TAC1 KNG1 BDNF
39 neuritis 30.0 IL6 CXCL8 BDNF
40 pulpitis 30.0 TRPV1 KNG1 IL6 CXCL8
41 constipation 29.9 TRPV1 TACR1 TAC1 IL6 BDNF
42 sleep apnea 29.9 TAC1 IL6 CXCL8 BDNF
43 gastroenteritis 29.9 IL6 CXCL8 CDH1
44 nerve compression syndrome 29.9 TRPV1 TAC1 NGF IL6
45 diabetic neuropathy 29.9 TRPV1 SCN9A NGF
46 complex regional pain syndrome 29.8 TACR1 TAC1 SCN9A IL6 CXCL8
47 suppression of tumorigenicity 12 29.8 IL6 EGF CXCL8 CDH1
48 pulmonary disease, chronic obstructive 29.8 TRPV1 TAC1 IL6 CXCL8
49 sudden infant death syndrome 29.8 TACR1 IL6 CXCL8 BDNF
50 chronic cystitis 29.8 UPK3A UPK1A TRPV1 TAC1 P2RX3 NGF

Comorbidity relations with Interstitial Cystitis via Phenotypic Disease Network (PDN):


Acute Cystitis Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Interstitial Cystitis:



Diseases related to Interstitial Cystitis

Symptoms & Phenotypes for Interstitial Cystitis

Human phenotypes related to Interstitial Cystitis:

58 31 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the menstrual cycle 58 31 hallmark (90%) Very frequent (99-80%) HP:0000140
2 abnormality of the urethra 58 31 hallmark (90%) Very frequent (99-80%) HP:0000795
3 dyspareunia 58 31 hallmark (90%) Very frequent (99-80%) HP:0030016
4 pollakisuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0100515
5 urinary urgency 58 31 hallmark (90%) Very frequent (99-80%) HP:0000012
6 urinary bladder inflammation 58 31 hallmark (90%) Very frequent (99-80%) HP:0100577
7 pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0012531
8 abnormality of the labia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000058
9 nocturia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000017
10 abnormal vagina morphology 31 occasional (7.5%) HP:0000142
11 abnormality of the bladder 58 Very frequent (99-80%)
12 abnormality of the genital system 58 Very frequent (99-80%)
13 abnormality of the vagina 58 Occasional (29-5%)
14 functional abnormality of the bladder 58 Very frequent (99-80%)

UMLS symptoms related to Interstitial Cystitis:


pain and other symptoms associated with female genital organs, mittelschmerz, unspecified symptom associated with female genital organs, other specified symptoms associated with female genital organs, female genital pain and other symptoms

MGI Mouse Phenotypes related to Interstitial Cystitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 CDH1 FZD8 HBEGF IL6 NGF P2RX3
2 growth/size/body region MP:0005378 10.03 BDNF CDH1 CKAP4 EGF HBEGF IL6
3 integument MP:0010771 9.97 BDNF CDH1 CKAP4 EGF HBEGF IL6
4 normal MP:0002873 9.61 BDNF CDH1 EGF FZD8 HBEGF NGF
5 renal/urinary system MP:0005367 9.23 FZD8 IL6 SCN9A TAC1 TJP1 TRPV1

Drugs & Therapeutics for Interstitial Cystitis

Drugs for Interstitial Cystitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 360)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desogestrel Approved Phase 4 54024-22-5 40973
2
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
3
Cycloserine Approved Phase 4 68-41-7 401 6234
4
Nitric Oxide Approved Phase 4 10102-43-9 145068
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
6
Belladonna Approved, Experimental Phase 4
7
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
8
Drospirenone Approved Phase 4 67392-87-4 68873
9
Tibolone Approved, Investigational Phase 4 5630-53-5
10
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
11
Danazol Approved Phase 4 17230-88-5 28417
12
Tranexamic Acid Approved Phase 4 1197-18-8 5526
13
Gemifloxacin Approved, Investigational Phase 4 175463-14-6 5464436 9571107
14
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
15
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
16
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
17
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
18
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
19
Ferrous fumarate Approved Phase 4 141-01-5
20
Azithromycin Approved Phase 4 83905-01-5 447043 55185
21
Misoprostol Approved Phase 4 59122-46-2 5282381
22
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
23
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
24
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
25
Ethanol Approved Phase 4 64-17-5 702
26
Hesperidin Approved, Investigational Phase 4 520-26-3 53477767
27
Polidocanol Approved Phase 4 9002-92-0
28
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
29
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
30
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
31
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
32
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
33
Sodium citrate Approved, Investigational Phase 4 68-04-2
34
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
35
Norepinephrine Approved Phase 4 51-41-2 439260
36
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
37
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
38
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
39
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
40
Gestodene Investigational Phase 4 60282-87-3 3033968
41
Resveratrol Investigational Phase 4 501-36-0 445154
42
BCG vaccine Investigational Phase 4
43 Viscosupplements Phase 4
44 Clindamycin phosphate Phase 4
45 Clindamycin palmitate Phase 4
46 Antioxidants Phase 4
47 Protective Agents Phase 4
48 Antitubercular Agents Phase 4
49 Gentamicins Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(show top 50) (show all 680)
# Name Status NCT ID Phase Drugs
1 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
2 Botulinum A Toxin Intravesical Injections Versus Bladder Overdistension in the Treatment of Patients With Painful Bladder Syndrome: A Prospective Randomized Study Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
3 Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain Unknown status NCT02213081 Phase 4 Ulipristal
4 Botox on Vulvar Vestibulitis Unknown status NCT00119886 Phase 4 Botulinum toxin
5 A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac Unknown status NCT01514175 Phase 4 IV Ibuprofen;IV Ketorolac
6 Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial. Unknown status NCT00844012 Phase 4 Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy);Cyclic OC (clormadinone acetate plus ethinil-estradiol)
7 Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis Unknown status NCT02237131 Phase 4 Oral contraceptives cyclic;Oral contraceptives continuous
8 Effectiveness of Self-cross-linked Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion Unknown status NCT02868437 Phase 4
9 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
10 A Randomized Clinical Trial Between Clindamycin Once and Thrice a Day in Septic Abortion. Unknown status NCT02309346 Phase 4 Clindamycin
11 The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4 Completed NCT02297100 Phase 4 Onabotulinumtoxin A
12 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
13 Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis Completed NCT01195116 Phase 4 Dexmedetomidine;Normal Saline
14 Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial Completed NCT00194610 Phase 4 Botox
15 To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
16 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial) Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
17 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
18 Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients Completed NCT02534688 Phase 4 LNG-IUS;DMPA
19 Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis Completed NCT02427386 Phase 4 dynamized estrogen;placebo
20 Effect of Nicotine on Chronic Pelvic Pain Completed NCT00440505 Phase 4 Placebo;Nicotine (5 mg);Nicotine (10 mg)
21 Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis Completed NCT02480647 Phase 4 Levonorgestrel;Etonogestrel
22 Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. Completed NCT01056042 Phase 4 intramuscular depot medroxyprogesterone acetate;ethinyl estradiol 30 micrograms, gestodene 75 micrograms
23 Efficacy of Paraspinous Anesthetic Block in Patients With Chronic Pelvic Pain Non-Responsive to Pharmacological Treatment Completed NCT01635205 Phase 4
24 The Impact of Local Estrogen on the Urogenital Microbiome in Genitourinary Syndrome of Menopause (GSM) Completed NCT03336437 Phase 4 Estradiol vaginal ring
25 Detection and Treatment Benefit of Microorganism (Chlamydia Trachomatis, Mycoplasma Hominis, Ureaplasma Urealyticum) in Overactive Bladder Patients Completed NCT00883818 Phase 4 azithromycin, doxycycline
26 The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial Completed NCT02475564 Phase 4 Placebo;Resveratrol
27 A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women Completed NCT00735852 Phase 4 Decapeptyl SR 11.25mg
28 Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide). Completed NCT01769781 Phase 4 anastrazole;GnRH analog alone
29 Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF Completed NCT01779232 Phase 4 Danazol;placebo
30 The Effect of Intracervical Lidocaine Injection Versus Topical Lidocaine Gel on the Pain Experienced by Patients Undergoing Tenaculum Application to the Cervix at the Time of an Office Gynecologic Procedure Completed NCT01421641 Phase 4 Intracervical Lidocaine Injection;Topical Lidocaine Gel
31 Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea? Completed NCT03124524 Phase 4 estradiol valerate/dienogest;ethinylestradiol and drospirenone
32 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
33 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
34 A Novel Analgesic Method for Postoperative Pain Relief After Cesarean Section: Intraoperative Superior Hypogastric Block Completed NCT03897764 Phase 4
35 Safety and Efficacy of Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy; A Randomized Controlled Trial Completed NCT03892668 Phase 4 Tranexamic Acid;oxytocin;placebo
36 Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea Completed NCT00926796 Phase 4 Azithromycin;Gentamicin;Gemifloxacin
37 Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin. Completed NCT02488642 Phase 4 Isosorbide Dinitrate;Misoprostol;Oxytocin
38 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
39 Interstitial Cystitis: Examination of the Central Autonomic Network Recruiting NCT03008382 Phase 4 Metoprolol Tartrate Oral Tablet;Placebo Oral Tablet
40 Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
41 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
42 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
43 The Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Fixation: A Randomized Trial Recruiting NCT03995641 Phase 4 marcaine and kenalog
44 A Randomized Controlled Trial (RCT) Comparing Presacral Nerve Block Versus Sham Block on Post-operative Pain in Women Undergoing Total Laparoscopic Hysterectomy. Recruiting NCT03646006 Phase 4 Bupivacaine;Placebo
45 The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0/7 and 22 6/7 Weeks Gestational Age Recruiting NCT04047849 Phase 4 Antibiotics, oral Azithromycin and oral Amoxicillin
46 A Prospective Cohort Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction Active, not recruiting NCT03199534 Phase 4 Botulinum toxin A 50u;Botulinum toxin A 100u;Botulinum toxin A 150u
47 IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial Not yet recruiting NCT04313972 Phase 4 low-dose naltrexone;Placebo oral tablet
48 Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome Not yet recruiting NCT04358497 Phase 4 Diosmin / Hesperidin;Ibuprofen 400 mg
49 Non-antimicrobial Alternative in Prophylaxis of Recurrent Urinary Tract Infections: a Prospective, Randomised-controlled, Double-blinded, Multicentre Study Not yet recruiting NCT04095572 Phase 4
50 Examining the Effects of Ketamine Treatment on Synaptic Plasticity in Depression Using PET Imaging Not yet recruiting NCT04091971 Phase 4 Ketamine

Search NIH Clinical Center for Interstitial Cystitis

Cochrane evidence based reviews: cystitis, interstitial

Genetic Tests for Interstitial Cystitis

Anatomical Context for Interstitial Cystitis

MalaCards organs/tissues related to Interstitial Cystitis:

40
Prostate, Testes, Brain, Kidney, Spinal Cord, Colon, Endothelial

Publications for Interstitial Cystitis

Articles related to Interstitial Cystitis:

(show top 50) (show all 3292)
# Title Authors PMID Year
1
Re: Management of Symptom Flares and Patient Reported Flair Triggers in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)-Findings from One Site of the MAPP Research Network. 61 42
32073949 2020
2
The clinical effect of traditional chinese medicine on middle-aged women with Interstitial Cystitis: Protocol for a randomized controlled trial. 42 61
32243402 2020
3
Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States. 42 61
31899034 2020
4
Efficacy and safety of over-the-counter analgesics for primary dysmenorrhea: A network meta-analysis. 42
32384431 2020
5
Deep gluteal syndrome as a cause of posterior hip pain and sciatica-like pain. 42
32349600 2020
6
Acupuncture combined with tamsulosin hydrochloride sustained-release capsule in the treatment of chronic prostatitis/chronic pelvic pain syndrome: A study protocol for a randomized controlled trial. 42
32195959 2020
7
Chlorogenic acid attenuates cyclophosphamide-induced rat interstitial cystitis. 61
32220624 2020
8
The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS? 61
32358624 2020
9
Response of hypogastric afferent fibers to bladder distention or irritation in cats. 61
32251646 2020
10
Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). 61
32509003 2020
11
Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome-A prospective, multicenter, randomized, double-blind, placebo-controlled study. 61
32394478 2020
12
Comments to Editorial by J. Curtis Nickel. It is premature to categorize Hunner lesion interstitial cystitis as a distinct disease entity. Scandinavian Journal of Urology 2020, Vol. 54, No. 2, 99-100. 61
32525741 2020
13
Pentosan polysulfate sodium-induced pigmentary maculopathy with non-leaking cystoid macular edema successfully treated with anti-VEGF therapy. 61
32541441 2020
14
Ceftriaxone inhibits stress-induced bladder hyperalgesia and alters cerebral micturition and nociceptive circuits in the rat: A multidisciplinary approach to the study of urologic chronic pelvic pain syndrome research network study. 61
32578247 2020
15
Non-bladder centric interstitial cystitis/bladder pain syndrome phenotype is significantly associated with co-occurring endometriosis. 61
32544050 2020
16
Re: Update on the Pathophysiology of Interstitial Cystitis/Bladder Pain Syndrome. 61
32567966 2020
17
Editorial Comment to Clinical guidelines for interstitial cystitis/bladder pain syndrome. 61
32542820 2020
18
Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives. 61
32246572 2020
19
Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics. 61
32281420 2020
20
Hunner Lesion Interstitial Cystitis: The Bad, The Good, and The Unknown. 61
32507337 2020
21
Platelet-Rich Plasma Ameliorates Cyclophosphamide-Induced Acute Interstitial Cystitis/Painful Bladder Syndrome in a Rat Model. 61
32521683 2020
22
Bioinformatics Approach for Identifying Novel Biomarkers and Their Signaling Pathways Involved in Interstitial Cystitis/Bladder Pain Syndrome with Hunner Lesion. 61
32575815 2020
23
Urease-Powered Polydopamine Nanomotors for Intravesical Therapy of Bladder Diseases. 61
32491832 2020
24
Opioid prescription use in patients with interstitial cystitis. 61
31980841 2020
25
Commentary on "Opioid prescription use in patients with interstitial cystitis". 61
32333063 2020
26
#Urogyn: What's Trending on Instagram? A Cross-sectional Observational Study. 61
32282524 2020
27
Urinary bladder sigma-1 receptors: A new target for cystitis treatment. 61
32105755 2020
28
Cranberry capsules are not superior to placebo capsules in managing acute non-haemorrhagic radiation cystitis in prostate cancer patients: A phase III double blinded randomised placebo controlled clinical trial. 61
32413530 2020
29
Physical exam in the evaluation of bladder pain syndrome (BPS): A key component for differential diagnosis. 61
32379063 2020
30
Inhibition of urease activity in the urinary tract pathogens Staphylococcus saprophyticus and Proteus mirabilis by dimethylsulfoxide (DMSO). 61
31860153 2020
31
A Comprehensive Review of the Diagnosis, Treatment, and Management of Urologic Chronic Pelvic Pain Syndrome. 61
32378039 2020
32
Long-standing nonulcerative bladder pain syndrome: Impact of Thiele massage on bladder and sexual domains. 61
31647172 2020
33
Efficacy of combination therapy with pentosan polysulfate sodium and adipose tissue-derived stem cells for the management of interstitial cystitis in a rat model. 61
32334368 2020
34
Comparison of the Efficacy Between Transurethral Coagulation and Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients: A Prospective Randomized Controlled Trial. 61
31959549 2020
35
Re: Verification of Mesenchymal Stem Cell Injection Therapy for Interstitial Cystitis in a Rat Model. 61
32396436 2020
36
Changes in uroplakin expression in the urothelium of patients with ulcerative interstitial cystitis/bladder pain syndrome. 61
32377607 2020
37
Potassium sensitivity test predicts hydrodistention efficacy in patients with bladder pain syndrome/interstitial cystitis. 61
31747364 2020
38
Pentosan Polysulfate-Associated Macular Disease in Patients With Interstitial Cystitis. 61
32282604 2020
39
Analysis of viruses present in urine from patients with interstitial cystitis. 61
32447589 2020
40
Does Obtaining a Diagnosis of Interstitial Cystitis/Bladder Pain Syndrome Improve Symptoms or Quality of Life? A Cross-Sectional Questionnaire-Based Study. 61
32304396 2020
41
Retinal Toxicity in a Patient on Pentosan Polysulfate Sodium. 61
32305545 2020
42
In-depth structural characterization of pentosan polysulfate sodium complex drug using orthogonal analytical tools. 61
32070534 2020
43
Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: an ESSIC working group report. 61
32107957 2020
44
Correlates of 1-Year Change in Quality of Life in Patients with Urologic Chronic Pelvic Pain Syndrome: Findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. 61
32294397 2020
45
Efficacy of Frankincense and Myrrha in Treatment of Acute Interstitial Cystitis/Painful Bladder Syndrome. 61
32279153 2020
46
It is premature to categorize Hunner Lesion interstitial cystitis as a distinct disease entity. 61
32216505 2020
47
Role of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Bladder Pain Syndrome/Interstitial Cystitis. 61
32277992 2020
48
Cultivable Bacteria in Urine of Women With Interstitial Cystitis: (Not) What We Expected. 61
32265402 2020
49
[Experimental evaluation of interaction of the nerve growth factor and mast cells in patients with interstitial cystitis/bladder pain syndrome]. 61
32351060 2020
50
Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome. 61
31833625 2020

Variations for Interstitial Cystitis

Expression for Interstitial Cystitis

Search GEO for disease gene expression data for Interstitial Cystitis.

Pathways for Interstitial Cystitis

Pathways related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.15 TRPV1 P2RX3 NGF IL6 HBEGF EGF
2
Show member pathways
12.82 TJP1 NGF IL6 HBEGF EGF CXCL8
3 12.52 KNG1 IL6 FZD8 EGF CXCL8 CDH1
4
Show member pathways
12.23 NGF IL6 EGF CDH1 BDNF
5
Show member pathways
12.13 IL6 HBEGF FZD8 EGF
6
Show member pathways
12.01 NGF IL6 HBEGF CXCL8 BDNF
7 11.95 IL6 FZD8 EGF CDH1
8 11.71 IL6 HBEGF EGF
9 11.64 TACR1 IL6 CXCL8 BDNF
10 11.62 NGF EGF BDNF
11 11.48 IL6 HBEGF CXCL8
12 11.45 IL6 EGF CXCL8
13 11.31 TACR1 TAC1 NGF IL6 CXCL8 BDNF
14 11.22 UPK3A HBEGF EGF CXCL8 CDH1
15 10.75 NGF IL6 EGF CXCL8 CDH1 BDNF
16 10.71 EGF BDNF
17 10.3 TACR1 TAC1

GO Terms for Interstitial Cystitis

Cellular components related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 UMOD TAC1 NGF KNG1 IL6 HBEGF
2 cell GO:0005623 9.87 TRPV1 TJP1 TACR1 TAC1 P2RX3 KNG1
3 extracellular space GO:0005615 9.81 UMOD TAC1 NGF KNG1 IL6 HBEGF
4 axon GO:0030424 9.77 TAC1 SCN9A P2RX3 NGF BDNF
5 plasma membrane GO:0005886 9.5 UPK3A UPK1A UMOD TRPV1 TJP1 TACR1
6 apical plasma membrane urothelial plaque GO:0120001 8.96 UPK3A UPK1A

Biological processes related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 IL6 HBEGF EGF
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.7 NGF IL6 BDNF
3 modulation of chemical synaptic transmission GO:0050804 9.69 P2RX3 NGF BDNF
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.62 TRPV1 TACR1 TAC1 KNG1
5 sensory perception of pain GO:0019233 9.58 TRPV1 TAC1 SCN9A
6 positive regulation of acute inflammatory response GO:0002675 9.57 TAC1 IL6
7 positive regulation of epidermal growth factor-activated receptor activity GO:0045741 9.55 HBEGF EGF
8 nerve growth factor signaling pathway GO:0038180 9.54 NGF BDNF
9 negative regulation of heart rate GO:0010459 9.49 TRPV1 TAC1
10 regulation of protein localization to cell surface GO:2000008 9.48 EGF BDNF
11 positive regulation of collateral sprouting GO:0048672 9.46 NGF BDNF
12 tachykinin receptor signaling pathway GO:0007217 9.43 TACR1 TAC1
13 urinary bladder smooth muscle contraction GO:0014832 9.37 TRPV1 P2RX3
14 response to pain GO:0048265 9.33 TRPV1 TACR1 TAC1
15 detection of abiotic stimulus GO:0009582 9.26 TACR1 TAC1
16 inflammatory response GO:0006954 9.17 TRPV1 TACR1 TAC1 SCN9A KNG1 IL6
17 behavioral response to pain GO:0048266 9.13 TRPV1 SCN9A P2RX3

Molecular functions related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.02 NGF IL6 HBEGF EGF BDNF
2 nerve growth factor receptor binding GO:0005163 8.96 NGF BDNF

Sources for Interstitial Cystitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....